De novo mutation in the mitochondrial ATP synthase subunit 6 gene (T8993G) with rapid segregation resulting in Leigh syndrome in the offspring
- PMID: 7649544
- DOI: 10.1007/BF00210409
De novo mutation in the mitochondrial ATP synthase subunit 6 gene (T8993G) with rapid segregation resulting in Leigh syndrome in the offspring
Abstract
The mutation in the mitochondrial ATP synthase subunit 6 gene (ATP6 T8993G) was identified in a male infant who died at age 15 months of Leigh syndrome. He had 94% mutated mitochondrial DNA (mtDNA) in muscle and 92% in lymphocytes. His mother was healthy but had 37% mutated mtDNA in muscle and 38% in lymphocytes. The proband's brother, who was also healthy, had 44% mutated mtDNA in lymphocytes. No mutated mtDNA was detected in muscle and lymphocytes from the maternal grandmother of the proband or in lymphocytes from 15 other maternal relatives, showing that the first carrier of the ATP6 T8993G mutation in this family was the mother of the proband. This study shows that this point mutation may occur at substantial levels in a carrier of a de novo mutation and rapid segregation with high levels of mutated mtDNA causing neurodegenerative disease may occur in the second generation.
Similar articles
-
[Leigh syndrome resulting from a de novo mitochondrial DNA mutation (T8993G)].Rev Neurol. 2002 Jun 16-30;34(12):1124-6. Rev Neurol. 2002. PMID: 12134275 Spanish.
-
Inheritance and expression of mitochondrial DNA point mutations.Biochim Biophys Acta. 1995 May 24;1271(1):249-52. doi: 10.1016/0925-4439(95)00035-3. Biochim Biophys Acta. 1995. PMID: 7599216
-
A second missense mutation in the mitochondrial ATPase 6 gene in Leigh's syndrome.Ann Neurol. 1993 Sep;34(3):410-2. doi: 10.1002/ana.410340319. Ann Neurol. 1993. PMID: 8395787
-
Leigh syndrome and hypertrophic cardiomyopathy in an infant with a mitochondrial DNA point mutation (T8993G).Am J Med Genet. 1994 Apr 15;50(3):265-71. doi: 10.1002/ajmg.1320500310. Am J Med Genet. 1994. PMID: 8042671 Review.
-
Long-term outcome of Leigh syndrome caused by the NARP-T8993C mtDNA mutation.Am J Med Genet A. 2007 Sep 1;143A(17):2046-51. doi: 10.1002/ajmg.a.31880. Am J Med Genet A. 2007. PMID: 17663470 Review.
Cited by
-
Mitochondrial DNA mutations at nucleotide 8993 show a lack of tissue- or age-related variation.J Inherit Metab Dis. 1999 Dec;22(8):899-914. doi: 10.1023/a:1005639407166. J Inherit Metab Dis. 1999. PMID: 10604142
-
Mitochondrial DNA sequence characteristics modulate the size of the genetic bottleneck.Hum Mol Genet. 2016 Mar 1;25(5):1031-41. doi: 10.1093/hmg/ddv626. Epub 2016 Jan 5. Hum Mol Genet. 2016. PMID: 26740552 Free PMC article.
-
Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome.Essays Biochem. 2018 Jul 20;62(3):455-465. doi: 10.1042/EBC20170113. Print 2018 Jul 20. Essays Biochem. 2018. PMID: 29950320 Free PMC article. Review.
-
Therapeutic Approaches to Treat Mitochondrial Diseases: "One-Size-Fits-All" and "Precision Medicine" Strategies.Pharmaceutics. 2020 Nov 11;12(11):1083. doi: 10.3390/pharmaceutics12111083. Pharmaceutics. 2020. PMID: 33187380 Free PMC article. Review.
-
De novo mtDNA point mutations are common and have a low recurrence risk.J Med Genet. 2017 Feb;54(2):73-83. doi: 10.1136/jmedgenet-2016-103876. Epub 2016 Jul 22. J Med Genet. 2017. PMID: 27450679 Free PMC article.